Retatrutide FDA & MHRA Approval Timeline: What Phase 3 Means for Regulatory Submissions

What Is the Current Regulatory Status of Retatrutide?

As of June 2026, retatrutide (LY3437943) is not approved by the FDA, the MHRA, or any other regulatory agency as a medicine for human use. It remains an investigational compound under active Phase 3 clinical development by Eli Lilly and Company. No New Drug Application (NDA) has been submitted to the FDA, and no Prescription Drug User Fee Act (PDUFA) target action date has been assigned.

This does not mean the compound is obscure or early-stage. As of the American Diabetes Association (ADA) 86th Scientific Sessions (6–9 June 2026), retatrutide has now produced positive topline results in multiple Phase 3 trials across obesity, type 2 diabetes, knee osteoarthritis, and obstructive sleep apnoea — a data package that Eli Lilly has described as sufficient to support regulatory filing.[1][2]

The compound is currently the only late-stage investigational drug to have demonstrated positive Phase 3 results as a triple agonist at the GLP-1, GIP, and glucagon receptors simultaneously. For background on its mechanism, see the Retatrutide Research Overview.

Which Phase 3 Trials Have Reported Results?

The Phase 3 programme for retatrutide is known as the TRIUMPH programme (for the obesity and complication trials) alongside the TRANSCEND programme (type 2 diabetes). The individual trials reported below are clinical pharmaceutical development trials conducted by Eli Lilly; they are summarised here as third-party scientific reference only, and are entirely separate from Velox Peptides' supply of retatrutide as an in vitro research reagent.

What Trials Are Still Pending?

Not all TRIUMPH programme trials have reported. Eli Lilly has indicated that additional Phase 3 readouts are expected during the second half of 2026. Based on public ClinicalTrials.gov listings and Lilly's published development disclosures, the key pending trials as of June 2026 are:

The TRIUMPH-3 cardiovascular outcomes trial is the most watched pending study. Cardiovascular outcomes trials (CVOTs) are now a standard expectation from both the FDA and MHRA for new obesity and metabolic medicines, and a positive CVOT could support a broader label and potentially accelerate review timelines. Whether Eli Lilly will wait for TRIUMPH-3 data before filing the NDA, or file on the existing data package and submit TRIUMPH-3 data as a post-approval commitment, has not been publicly confirmed.

When Is Eli Lilly Expected to File the NDA?

On its Q1 2026 earnings call, Eli Lilly confirmed it plans to file a New Drug Application (NDA) in Q4 2026 for retatrutide in obesity, following the completion of the TRIUMPH-1 data package.[8] This was the company's first public commitment to a filing window following the December 2025 TRIUMPH-4 readout.

An NDA is the formal dossier submitted to the FDA containing all preclinical, clinical, safety, manufacturing, and labelling information for a new drug. For retatrutide, the core NDA dataset is expected to include:

• Phase 1 pharmacokinetics and safety data (published in The Lancet, 2022)[9]
• Phase 2 randomised trial data (published in NEJM, 2023)[10]
• Phase 3 TRIUMPH-4 (obesity + OA), TRIUMPH-1 (pivotal obesity), TRANSCEND-T2D-1 (T2D)
• Long-term safety and tolerability data from all Phase 3 arms
• Manufacturing process validation and quality/CMC documentation

The NDA will most likely seek an initial indication in chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, mirroring the TRIUMPH-1 enrolment criteria. Whether a type 2 diabetes indication will be filed simultaneously or as a subsequent supplemental NDA is not yet publicly confirmed.

How Does the FDA Review Process Work, and When Could Approval Come?

Once an NDA is accepted for filing, the FDA assigns a PDUFA (Prescription Drug User Fee Act) target action date — the deadline by which the agency aims to complete its review. The standard review target is 10 to 12 months from NDA acceptance. The FDA may also grant priority review (reducing the target to six months) for new medicines that offer a significant improvement over existing therapies. Whether Lilly will seek priority review for retatrutide has not been publicly announced.

Under the most likely scenario — Q4 2026 NDA filing, standard 10-to-12 month review — the projected FDA decision window is:

These timelines are estimates based on publicly available information and standard FDA review processes. They are not regulatory commitments and are subject to change based on FDA review findings, any advisory committee meetings, NDA content requirements, or clinical holds.

What Is the UK MHRA Timeline?

Since Brexit, the MHRA (Medicines and Healthcare products Regulatory Agency) operates independently from the European Medicines Agency (EMA) and the FDA. The MHRA has introduced several accelerated pathways including the Innovative Licensing and Access Pathway (ILAP) and accelerated assessment, but approvals for new medicines typically follow the US or EU by months to years depending on when Lilly submits a Marketing Authorisation Application (MAA) to the MHRA.

For context, tirzepatide (Mounjaro) received FDA approval in May 2022 and MHRA approval in November 2023 — a gap of approximately 18 months. Semaglutide (Wegovy) received FDA approval in June 2021 and MHRA approval in January 2023 — also approximately 18 months. Based on these precedents, a retatrutide MHRA decision is most likely to fall in 2028, assuming a Q4 2026 NDA filing, late 2027 FDA approval, and a parallel or near-parallel MHRA submission by Eli Lilly.

How Do Retatrutide Phase 3 Results Compare With Approved Medicines?

The table below compares reported Phase 3 trial findings across three compounds in the GLP-1 class. These are results from separate trials with different designs, durations, and enrolment criteria — they are not the product of a direct head-to-head comparison and should not be used as such. Retatrutide data is from the TRIUMPH-1 Phase 3 trial (80 weeks); semaglutide data is from STEP-1 (68 weeks); tirzepatide data is from SURMOUNT-1 (72 weeks).

The larger reported weight reductions in the retatrutide TRIUMPH-1 trial compared to earlier trials of semaglutide and tirzepatide are of considerable interest to researchers studying incretin receptor pharmacology. It is important to note that direct head-to-head trials between retatrutide and these agents have not been published. The differences in trial design, patient population, duration, and dose-escalation protocols mean cross-trial comparisons are indicative only. For a more detailed receptor-by-receptor comparison, see the Retatrutide vs Tirzepatide vs Semaglutide guide.

Retatrutide for In Vitro Research: Current Availability

The regulatory pathway described above relates to retatrutide's development as a licensed human pharmaceutical medicine by Eli Lilly. This is separate from, and does not affect, the availability of retatrutide as an in vitro research reagent in the UK.

Research-use retatrutide is legally available in the UK for laboratory purposes and does not require MHRA approval in the same way that a licensed medicine does. Velox Peptides supplies retatrutide (LY3437943) as a lyophilised research reagent — HPLC-verified at ≥99% purity with batch documentation available on request — dispatched from Northern Ireland with next-day UK delivery. The compound is used in academic and commercial research settings studying GLP-1, GIP, and glucagon receptor pharmacology.

Retatrutide is supplied as a research reagent. It is not a medicine. It is not approved by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy.

Frequently Asked Questions